22,905 Shares in Vera Therapeutics, Inc. $VERA Bought by Monashee Investment Management LLC

Monashee Investment Management LLC purchased a new position in Vera Therapeutics, Inc. (NASDAQ:VERA) in the fourth quarter, HoldingsChannel reports. The fund purchased 22,905 shares of the company’s stock, valued at approximately $1,160,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Deerfield Management Company L.P. increased its stake in shares of Vera Therapeutics by 8.8% in the third quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock worth $105,812,000 after buying an additional 293,040 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Vera Therapeutics by 11.9% in the fourth quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock worth $180,805,000 after buying an additional 379,748 shares during the last quarter. Vestal Point Capital LP increased its stake in shares of Vera Therapeutics by 24.0% in the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock worth $73,036,000 after buying an additional 600,000 shares during the last quarter. Integral Health Asset Management LLC increased its stake in shares of Vera Therapeutics by 47.8% in the third quarter. Integral Health Asset Management LLC now owns 1,700,000 shares of the company’s stock worth $49,402,000 after buying an additional 550,000 shares during the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Vera Therapeutics by 9.3% in the fourth quarter. Geode Capital Management LLC now owns 1,444,925 shares of the company’s stock worth $73,185,000 after buying an additional 123,350 shares during the last quarter. Institutional investors own 99.21% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. Wolfe Research upgraded shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 target price for the company in a research note on Wednesday, March 11th. The Goldman Sachs Group reiterated a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. HC Wainwright boosted their target price on shares of Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Finally, William Blair reiterated an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Ten analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $78.00.

Vera Therapeutics Stock Up 6.4%

Vera Therapeutics stock opened at $33.65 on Friday. The company has a 50-day simple moving average of $37.14 and a 200-day simple moving average of $41.43. The firm has a market capitalization of $2.42 billion, a P/E ratio of -6.07 and a beta of 0.93. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. Vera Therapeutics, Inc. has a one year low of $19.07 and a one year high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) EPS for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period last year, the company posted ($0.81) EPS. As a group, equities analysts expect that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current year.

Insider Activity at Vera Therapeutics

In other news, CEO Marshall Fordyce sold 22,951 shares of the company’s stock in a transaction dated Tuesday, April 14th. The shares were sold at an average price of $44.05, for a total transaction of $1,010,991.55. Following the completion of the transaction, the chief executive officer owned 235,244 shares in the company, valued at approximately $10,362,498.20. This represents a 8.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 15.90% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.